Terms for switches in inflation-linked bond SGB IL 3102 The

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
14
Terms for switches in inflation-linked bond SGB IL 3102

The Swedish National Debt Office (SNDO) offers switch auctions in inflation-linked bond SGB IL 3102 with the aim of decreasing the outstanding volume to around SEK 25 billion before the bond's time to maturity is shorter than one year. The first switch auctions will be held on 8 and 11 March.

The offered bonds in the switch auctions are SGB IL 3112 and SGB IL 3109. Switches versus SGB IL 3112 will be price risk neutral [1] while switches versus SGB IL 3109 will be cash neutral [2] .

Switch auctions
  Fri 8 March Risk neutral Mon 11 March Cash neutral
SNDO sells bond  3112 3109
SNDO sells amount (SEK mn) 500 750
SNDO buys bond  3102 3102
SNDO buys amount (SEK mn) [3] 1 600 600
Time for yield on buy-back loan 10:45 10:45
Time for auction cut-off 11:00 11:00
Time for auction result 11:03 11:03

The switches were announced in the publication Central Government Borrowing - Forecast and Analysis 2018:3 in October .

The buy-back yield will be published at 10:45 a.m. on the day of the auction on riksgalden.se/borrowing .

Bids must be placed before 11:00 a.m. on the day of the auction. The results will be published at 11:03 a.m. or somewhat later. Bidding is only possible by primary dealers.

For more information, please contact: Anna Sjulander, Head of Funding, +46 (0)8 613 47 77 Magdalena Belin, Head of Analysis, +46 (0)8 613 52 28

[1] The market value of the purchase and sales volume multiplied by the modified duration of each respective bond shall be equal.

[2 ] The market value of the purchase and sales volume of each bond shall be equal.

[3] The stated nominal volume of SGB IL 3102 is an approximation calculated on the basis of today's yields.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading